![](/images/graphics-bg.png)
A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia
المؤلفون المشاركون
Chen, Hongdou
Wang, Jin-na
Wang, Xu
Yu, Shu-le
Ding, Yue-hui
Wang, Meng-lei
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-04-30
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Objective.
To evaluate the difference of clinical efficacy of peramivir alone and peramivir combined with immunomodulators (either ribonucleic acid or thymopetidum) in the treatment of severe influenza A with primary viral pneumonia.
Methods.
A retrospective analysis was applied to 45 patients who were diagnosed with severe influenza A with primary viral pneumonia in our hospital from December 2017 to March 2018.
The cases were divided into three groups: the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group.
Results.
The duration of viral nucleic acid positivity in the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 6.13 ± 2.06, 6.53 ± 2.72, and 6.10 ± 1.37 days, respectively.
The remission time of the clinical symptoms of the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 8.06 ± 2.73, 7.94 ± 2.89, and 7.67 ± 1.58 days, respectively.
Comparisons between the peramivir group and the peramivir combined with ribonucleic acid group or the peramivir combined with thymopetidum group revealed no significant differences in the duration of virus nucleic acid positivity, remission time of clinical symptoms, time to fever alleviation, and time to cough alleviation.
Conclusions.
There is no observed benefit in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia.
This trial is registered with ChiCTR1800019417.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wang, Jin-na& Wang, Xu& Yu, Shu-le& Ding, Yue-hui& Wang, Meng-lei& Chen, Hongdou. 2019. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wang, Jin-na…[et al.]. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wang, Jin-na& Wang, Xu& Yu, Shu-le& Ding, Yue-hui& Wang, Meng-lei& Chen, Hongdou. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1145716
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)